Please login to the form below

Not currently logged in
Email:
Password:

biosimilar

This page shows the latest biosimilar news and features for those working in and with pharma, biotech and healthcare.

Roche preps filings for Herceptin/Perjeta combination

Roche preps filings for Herceptin/Perjeta combination

Potential defence against biosimilar competition. A fixed-dose combination of Roche’s antibody blockbusters Herceptin and Perjeta has cleared a phase 3 trial, promising simpler dosing of the breast cancer drugs – ... IV Herceptin biosimilars from

Latest news

More from news
Approximately 135 fully matching, plus 316 partially matching documents found.

Latest Intelligence

  • Transitions in healthcare Transitions in healthcare

    Switching from an originator biologic to a cheaper biosimilar. These are all examples of the kind of treatment transitions patients experience that can be supported by Patient Support Programmes.

  • It’s not the end of the world, is it? It’s not the end of the world, is it?

    Whether we market branded products that offer no real superiority over generics, biosimilars or me-toos or we sell innovative products whose price differential is not financially justified, much of what

  • Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019 Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019

    It will compete with numerous treatment modalities, including entrenched biological agents and biosimilar biologicals.

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    The world’s biggest selling drug, Humira, lost its market exclusivity in Europe to biosimilar competition in 2018, and AbbVie is well aware of the impending US patent expiry in 2022. ... Finally, 2019 will see a rapid increase in the uptake of Humira

  • Deal Watch October 2018

    None of the other biosimilars in the agreement between the two companies, in the fields of oncology and immunology, are affected. ... Sandoz’s US business has retained its biosimilars, value‐added medicines and complex generics, including the

More from intelligence
Approximately 11 fully matching, plus 56 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 15 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 13 fully matching, plus 24 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

Alzheimers incidence
A roadmap to the successful treatment of Alzheimer’s disease
Building on past research to learn more about the disease and how to treat it...
Article: Like, Like, Like: Harnessing the power of social media insights
...
Its Know Your Numbers week
Do you know yours?...

Infographics